吡柔比星与丝裂霉素C膀胱灌注预防TURBt术后浅表性膀胱尿路上皮癌复发的临床研究  

Bladder instillation of pirarubicin combined with mitomycin C for prevention of TURBt postoperative superficial bladder urothelial carcinoma recurrence

作　　者：黄红星[1] 李志坚[1] 曹彬[1] 

机构地区：[1]广东省中山市人民医院泌尿外科,广东中山528403

出　　处：《海南医学院学报》2013年第4期504-506,共3页Journal of Hainan Medical University

基　　金：中国高校医学期刊临床专项资金项目(112210599)~~

摘　　要：目的:研究膀胱癌术后应用吡柔比星(THP)或丝裂霉素C(MMC)膀胱灌注预防TURBt术后浅表性膀胱尿路上皮癌复发的效果。方法:将78例膀胱癌术后患者随机分成两组,一组40例患者膀胱灌注THP,另一组38例患者膀胱灌注MMC,THP组总疗程12个月,MMC组总疗程2年,期间观察复发情况及不良反应。结果:THP组2年内复发率及不良反应发生率分别为15.0%(6/40)和27.5%(11/40);MMC组2年内复发率及不良反应发生率分别为28.9%(11/38)和31.6%(12/38)。两组肿瘤复发率有显著差异(P<0.05),不良反应发生率无明显差异(P<0.05)。结论:THP膀胱灌注化疗预防膀胱癌术后复发,较MMC疗效好,是目前较为理想的膀胱灌注药物,但是费用较高;MMC疗效虽没有THP好,但是费用较低,因而亦常用MMC作为预防膀胱癌术后复发。Objective： To investigate the efficiency of bladder instillation of pirarubicin （THP） combined with mitomyein C （MMC） for prevention of TURBt postoperative superficial bladder urothelial carcinoma recurrence. Methods： A total of 78 patients underwent carcinoma of the urinary bladder surgery were randomly divided into two groups, one group （40 patients） was treated with bladder instillation of pi- rarubicin （THP） for a course of 12 months and the other （38 patients） was dealt with bladder instillation of mitomycin C（MMC） for 2 years. Recurrence and side effects were observed and compared. Results. In the THP group, 2-year recurrence rate and adverse reaction rates were 15.0% and 27. 5%, respectively, and the corresponding data of the MMC group were 28.9% and 31.6% of MMC group. Significant differ-ence in recurrence rate was observed （P^O. 01）. Conclusions： THP bladder perfusion shows better effe- ciency for prevention of postoperative recurrence of bladder cancer than MMC. MMC is also commonly used because it is cheaper.

关 键 词：吡柔比星 丝裂霉素C 膀胱灌注 复发 预防 

分 类 号：R737.14[医药卫生—肿瘤]